Moustapha El-Amine, Ph.D. Joins Insmed Incorporated as Executive Director of Global Search and Evaluation (S&E)
Moustapha El-Amine, Ph.D. has joined Insmed Incorporated as Executive Director of Global Search and Evaluation (S&E). Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. In this position, El-AMine will lead the Search and Evaluation activities of the company across all stages of R&D, from research platforms and pre-clinical compounds to late-stage clinical assets and inline products.
El-Amine will play an instrumental role in driving the expansion of the company’s pipeline by sourcing and evaluating high-potential assets, licensing opportunities, and collaborations in alignment with the strategic priorities of the company.
Before Insmed, El-Amine was Sr. Director and Global Head of S&E Immunology Department at AbbVie, leading Ventures, BD search and evaluation activities for in-licensing and partnering. His previous roles include the Director of Global Search & Evaluation at AstraZeneca (AZ), Sr. Director and Head of the Scientific Affairs department at Emergent Biosolutions Inc. (EBS). Additionally, El-Amine was a Principal Investigator at Dynport Vaccines (DVC) managing a vaccine program for DoD (US Department of Defense) and before that, he led the patch vaccine program at Iomai corp, for the US military and the development of a skin delivered cancer vaccine.
El-Amine also serves on the advisory board of East-West Resources (EWR), a boutique venture fund covering the US, and East-West Protection (EWP) a biodefense venture fund, he is also member of the Commercial Relevance Advisory Board (CRAB) as part of BioHealth Innovation (BHI) serving the State of Maryland.
Mous has a BS in Biology from the American university of Beirut (AUB), a Masters in Molecular Endocrinology from Laval University (Quebec, Canada), a PhD in Cell biology/Immunology from Sherbrooke University (Sherbrooke, Canada), a Masters in Biotechnology and an MBA from Johns Hopkins University, Carey School of Business (Baltimore, Maryland).
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed’s earlier-stage clinical pipeline includes brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Latest posts by Chris Frew (see all)
- Dr. Anthony Fauci & AGT’s Jeff Galvin Join ‘I AM BIO’ to Discuss Future of HIV Treatments - September 14, 2021
- Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago | Business Wire - September 7, 2021
- VaLogic acquires vacant Frederick building to create tech hub - August 31, 2021
- New Frederick facility delivers in-demand lab, workspace for growing biotech firms - August 27, 2021
- Intralytix Receives Fast Track NIH SBIR Contract to Develop a Universal, Scale-independent AI-based Platform for Manufacturing High Titer Bacteriophage Preparations for Clinical Applications - August 18, 2021